A soaring growth stock I’d buy ahead of Fevertree Drinks plc

Fevertree Drinks plc (LON: FEVR) shares have soared, but is this growth stock set to overtake them?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The growth story at Fevertree Drinks (LSE: FEVR) has been impressive. The shares have quadrupled over the past four years and have soared by 1,300% over five years — and all the company makes is drinks mixers.

But they’re big business these days, with trendy drinkers wanting all sorts of variations rather than just the traditional soda water, tonic, etc.

But three things convince me the bull run is coming to an end, and I’d sell if I owned any.

You know the idea that when even the folks down the pub are talking about a stock, it’s time to sell? I witnessed the equivalent on TV last week — I wasn’t paying attention, but some ‘reality’ person said their favourite drink would be something or other “with a nice Fevertree mixer.” 

Competition

Another thing is that I really don’t see a defensive moat around Fevertree’s business model, and nothing to prevent other makers moving into the premium mixer market (which they’re already doing).

Finally, it’s the share price chart itself and the shares’ fundamental valuation. I’ve seen the same thing happening to growth darlings just too many times, and it almost always ends in a crash after the climb. Fevertree shares have already shown their first sign of weakening with a dip towards the end of 2017 — it’s come back, but that often signals the final wave of bandwagon buyers.

The initial rapid EPS growth is set to slow, with just 9% on the cards for 2018 — yet with the shares at 2,316p, we’re still looking at a forward P/E of 54. I really see that as overvalued now, and I’d walk away.

Another climber

Healthcare software specialist Craneware (LSE: CRW) has been a success for shareholders too, with its shares up fourfold in five years to 1,715p.

Its earnings growth has been at a more leisurely pace than Fevertree’s, but investors have high hopes of it continuing for many years to come. And I reckon a forward P/E of 35 based on June 2019 forecasts has just become a good bit more attractive.

The company has announced two new hospital contracts with new US customers, and they look like they could have some serious potential. We don’t know the names of them yet, but one is “a large blue-chip healthcare provider” which will use Craneware’s products in its 20 hospitals.

Craneware says this will be as “an integral part of this provider’s major system change“, which sounds like it’s in at the beginning and could be a long-term partner. The deal should bring in revenue of around $5m in its initial multi-year term.

The second new agreement, estimated to be worth around $3.5m in its initial term, is with “an innovative surgical hospital” and involves the supply of a number of Craneware’s software packages.

Continuing trend

This comes on the back of a number of other contract wins, with the most recent announced in January expected to provide $16m in revenue over five years.

At the same time, the firm told us it expects EBITDA to come in 15%-18% ahead for the six months to December 2017. The balance sheet looks good too, with cash of more than $50m on the books.

There’s clearly some momentum behind Craneware right now — in its share price, and more importantly, in its contract developments too. I see good long-term value.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended Craneware. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Value Shares

After a 16% drop, FTSE 100 stock JD Sports Fashion looks like a steal to me

This FTSE 100 stock has tanked since mid-September. Edward Sheldon believes that there's value on offer after the share price…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Is now the time to buy BP shares? Here’s what the charts say

The best time to buy shares in a company is when they’re trading at a discount. But the future is…

Read more »

Investing Articles

Here’s how I’d use £50K to aim for a million when the stock market crashes

Seeing a stock market crash as a buying opportunity could prove lucrative for a well-prepared, long-term investor. Christopher Ruane explains…

Read more »

Stack of one pound coins falling over
Investing Articles

It’s up 27% with a P/E of 9! I’m considering the potential of this blossoming penny stock

Despite several years of losses, this UK penny stock has an impressive valuation. I’m looking to see if it could…

Read more »

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »